Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation
Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation
复制标题
DOI：
10.1038/modpathol.2011.52
复制
发表时间：
2011-07-01
期刊：
影响因子：
7.5
通讯作者：
Walch, Axel
中科院分区：
文献类型：
--
作者：
Langer, Rupert;Rauser, Sandra;Walch, Axel
ErbB 2（Her 2）的扩增和过表达是食管腺癌中的常见事件。评估ErbB 2状态对于识别可能从曲妥珠单抗治疗中获益的患者至关重要。在这项研究中，我们进行了一个全面的分析ErbB 2扩增和表达在142食管腺癌通过比较最常用的方法ErbB 2的评估：ErbB 2的表达通过免疫组化测定，并根据最近描述的胃癌评分系统评分（0，1 +，2 +和3 +）。ErbB 2扩增通过明视野双重原位杂交进行评估。结果与病理特征，患者的生存率和先前发表的荧光原位杂交分析数据进行了比较。基于免疫组织化学，适用于110个核心病例，83个肿瘤（75%）评分为0或1 +（免疫组织化学阴性），13个肿瘤（12%）评分为2 +，14个肿瘤（13%）评分为3 +。原位杂交数据来自142个病例。免疫组化、明视野原位杂交和荧光原位杂交具有高度显著的相关性（P= 2，如通过明视野双重原位杂交或荧光原位杂交评估的。ErbB 2阳性率在分化程度较低的肿瘤中更常见（P = 0.029）。单因素分析（P = 0.004）和多因素分析（P = 0.03）显示，ErbB 2阳性肿瘤患者的预后明显较差。总之，我们证明，一个显着的食管腺癌的ErbB 2阳性。ErbB 2扩增的评估可以等效地通过常规的荧光原位杂交或其他基于光学显微镜的方法进行，例如新的明视野双原位杂交技术。Modern Pathology（2011）24，908-916; doi：10.1038/modpathol.2011.52; 2011年4月22日在线发表
Amplification and overexpression of ErbB2 (Her2) is a frequent event in oesophageal adenocarcinomas. Assessment of ErbB2 status is crucial for identifying patients who are likely to benefit from treatment with trastuzumab. In this study, we performed a comprehensive analysis of ErbB2 amplification and expression in 142 oesophageal adenocarcinomas by comparing the most commonly used methods for ErbB2 assessment: ErbB2 expression was determined by immunohistochemistry and was scored (0, 1 +, 2 + and 3 +) according to a recently described modified scoring system for gastric cancer. ErbB2 amplification was evaluated by bright field double in situ hybridisation. The results were compared with pathologic features, patients' survival and previously published data from fluorescence in situ hybridisation analysis. On the basis of immunohistochemistry, which was applicable in 110 cores of the cases, 83 tumours (75%) had a score of 0 or 1 + (immunohistochemistry negative), 13 tumours (12%) were scored as 2 + and 14 tumours (13%) were scored as 3 +. In situ hybridisation data were obtained from 142 cases. There was a highly significant correlation of immunohistochemistry, bright field in situ hybridisation and fluorescent in situ hybridisation (P= 2 as assessed by either bright field double in situ hybridisation or fluorescence in situ hybridisation. ErbB2 positivity was observed more frequently in tumours with lower differentiation grades (P = 0.029). Patients with ErbB2-positive tumours had a significantly worse prognosis, both in univariate analysis (P = 0.004) and in multivariate analysis (P = 0.03). In conclusion, we demonstrate that a significant number of oesophageal adenocarcinomas are positive for ErbB2. Assessment of ErbB2 amplification can be equivalently performed by conventional fluorescence in situ hybridisation or other light-microscopy-based methods, such as the novel bright field double in situ hybridisation technique. Modern Pathology (2011) 24, 908-916; doi: 10.1038/modpathol.2011.52; published online 22 April 2011